{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:51:40Z","timestamp":1747194700475,"version":"3.40.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There has been a paradigm shift in the treatment of Hepatitis C (HCV) from the interferon-era to direct-acting antiviral (DAA) drugs. Cure of HCV for the key risk group, those with a history of injecting drug use, may provide a range of benefits to an individual\u2019s quality of life that can be additional to that of a clinical cure. The interferon-era provided evidence that cure of HCV can be a turning point for those who use drugs, supporting a recovery journey. There remains a question if DAAs can provide the same opportunity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We employed a scoping review methodology to consider the additional non-clinical benefits that HCV cure may provide. We used the theoretical construct of recovery capital to consider how these benefits may support a recovery journey in the DAA-era.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our search provided 2095 articles, from which 35 were included in the analysis. We developed a thematic synthesis of the non-clinical outcomes identified based on the four over-arching themes of recovery capital: physical, cultural, social and human capital. Our review suggests that identity change is a constituent part of each of the recovery capital domains in relation to HCV treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We identified Social Identity Model Of Recovery (SIMOR) as a mechanism through which DAAs may provide non-clinical outcomes to increase recovery capital domains. Further research is required to develop an understanding of the impact a cure of HCV with DAAs may have on identity, overall health and wellbeing and social inclusion to support recovery journeys.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-022-00475-1","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T21:02:20Z","timestamp":1654722140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Future destinations and social inclusion\u00a0scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-3293","authenticated-orcid":false,"given":"Sarah R.","family":"Donaldson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-2388","authenticated-orcid":false,"given":"Andrew","family":"Radley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4476","authenticated-orcid":false,"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"475_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102714","volume":"78","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Sacamano P, McCormick SD, Yang C, Kirk G, Thomas D, et al. Individual and network factors associated with HCV treatment uptake among people who inject drugs. Int J Drug Policy. 2020;78:102714.","journal-title":"Int J Drug Policy"},{"key":"475_CR2","unstructured":"WHO. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: World health Organization; 2016."},{"key":"475_CR3","volume-title":"Hepatitis C among drug users in Europe: epidemiology, Treatment and prevention","author":"European monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2016","unstructured":"European monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hepatitis C among drug users in Europe: epidemiology, Treatment and prevention. Luxembourg: Publications Office of the European Union; 2016."},{"issue":"3","key":"475_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/16066359.2018.1515352","volume":"27","author":"RD Ashford","year":"2019","unstructured":"Ashford RD, Brown A, Brown T, Callis J, Cleveland HH, Eisenhart E, et al. Defining and operationalizing the phenomena of recovery: a working definition from the recovery science research collaborative. Addict Res Theory. 2019;27(3):179\u201388.","journal-title":"Addict Res Theory"},{"issue":"3","key":"475_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jsat.2007.06.001","volume":"33","author":"The Betty Ford Institute Consensus Panel","year":"2007","unstructured":"The Betty Ford Institute Consensus Panel. What is recovery? A working definition from the Betty ford institute. J Subst Abus Treat. 2007;33(3):221\u20138.","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"475_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jsat.2007.04.015","volume":"33","author":"WL White","year":"2007","unstructured":"White WL. Addiction recovery: its definition and conceptual boundaries. J Subst Abus Treat. 2007;33(3):229\u201341.","journal-title":"J Subst Abus Treat"},{"key":"475_CR7","volume-title":"The potential of recovery capital","author":"D Best","year":"2010","unstructured":"Best D, Laudet A. The potential of recovery capital. London: RSA; 2010."},{"key":"475_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugalcdep.2017.09.002","volume":"181","author":"I Cano","year":"2017","unstructured":"Cano I, Best D, Edwards M, Lehman J. Recovery capital pathways: Modelling the components of recovery wellbeing. Drug Alcohol Depend. 2017;181:11\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"12\u201313","key":"475_CR9","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1080\/10826080802289762","volume":"43","author":"W Cloud","year":"2008","unstructured":"Cloud W, Granfield R. Conceptualizing recovery capital: expansion of a theoretical construct. Subst Use Misuse. 2008;43(12\u201313):1971\u201386.","journal-title":"Subst Use Misuse"},{"issue":"5","key":"475_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/16066359.2017.1297990","volume":"25","author":"EA Hennessy","year":"2017","unstructured":"Hennessy EA. Recovery capital: a systematic review of the literature. Addict Res Theory. 2017;25(5):349\u201360.","journal-title":"Addict Res Theory"},{"key":"475_CR11","unstructured":"WHO. Combating hepatitis B and C to reach elimination by 2030: advocacy brief: World health Organization; 2016."},{"issue":"3","key":"475_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0165-0327(02)00264-1","volume":"72","author":"S Bonaccorso","year":"2002","unstructured":"Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72(3):237\u201341.","journal-title":"J Affect Disord"},{"issue":"5","key":"475_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/1363459314555237","volume":"19","author":"JA Clark","year":"2014","unstructured":"Clark JA, Gifford AL. Resolute efforts to cure hepatitis C: understanding patients\u2019 reasons for completing antiviral treatment. Health. 2014;19(5):473\u201389.","journal-title":"Health"},{"key":"475_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.drugpo.2018.07.015","volume":"60","author":"M Harris","year":"2018","unstructured":"Harris M, Rhodes T. Caring and curing: considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. Int J Drug Policy. 2018;60:24\u201332.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"475_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/1363459309358597","volume":"14","author":"H K\u00f6rner","year":"2010","unstructured":"K\u00f6rner H. Negotiating treatment for hepatitis C: interpersonal alignment in the clinical encounter. Health. 2010;14(3):272\u201391.","journal-title":"Health"},{"issue":"2","key":"475_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.drugpo.2013.11.004","volume":"25","author":"L Jones","year":"2014","unstructured":"Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, et al. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Policy. 2014;25(2):204\u201311.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"475_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1155\/2013\/515636","volume":"27","author":"AI Newman","year":"2013","unstructured":"Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, et al. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health Centre. Can J Gastroenterol. 2013;27(4):217\u201323.","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"475_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/add.12392","volume":"109","author":"J Rance","year":"2014","unstructured":"Rance J, Treloar C, ETHOS Study Group. \u2018Not just M ethadone T racy\u2019: transformations in service-user identity following the introduction of hepatitis C treatment into a ustralian opiate substitution settings. Addiction. 2014;109(3):452\u20139.","journal-title":"Addiction."},{"issue":"7","key":"475_CR19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/1467-9566.12018","volume":"35","author":"T Rhodes","year":"2013","unstructured":"Rhodes T, Harris M, Martin A. Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. Sociol Health Illness. 2013;35(7):1023\u201344.","journal-title":"Sociol Health Illness"},{"issue":"9","key":"475_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348.","journal-title":"Ann Intern Med"},{"issue":"5","key":"475_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. European Association for the Study of the liver. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"key":"475_CR22","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","volume":"26","author":"P Bruggmann","year":"2015","unstructured":"Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:S22\u2013S6.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"475_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","volume":"67","author":"JV Lazarus","year":"2017","unstructured":"Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination\u2013a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665\u20136.","journal-title":"J Hepatol"},{"issue":"1","key":"475_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","volume":"19","author":"A Radley","year":"2019","unstructured":"Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19(1):765.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"475_CR25","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/cid\/ciz546","volume":"70","author":"AJ Wade","year":"2020","unstructured":"Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900\u20136.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"475_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugpo.2003.10.009","volume":"15","author":"M Davis","year":"2004","unstructured":"Davis M, Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. Int J Drug Policy. 2004;15(2):123\u201331.","journal-title":"Int J Drug Policy"},{"key":"475_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugpo.2019.06.002","volume":"72","author":"J Bryant","year":"2019","unstructured":"Bryant J, Rance J, Hull P, Mao L, Treloar C. Making sense of \u2018side effects\u2019: Counterpublic health in the era of direct-acting antivirals. Int J Drug Policy. 2019;72:77\u201383.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"475_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"issue":"3","key":"475_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","volume":"13","author":"MD Peters","year":"2015","unstructured":"Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthcare. 2015;13(3):141\u20136.","journal-title":"Int J Evid Based Healthcare"},{"issue":"7","key":"475_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"10","key":"475_CR31","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MD Peters","year":"2020","unstructured":"Peters MD, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synthesis. 2020;18(10):2119\u201326.","journal-title":"JBI Evid Synthesis"},{"key":"475_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354.","journal-title":"Drug Alcohol Depend"},{"key":"475_CR33","doi-asserted-by":"publisher","first-page":"3268650","DOI":"10.1155\/2017\/3268650","volume":"2017","author":"LE Dowsett","year":"2017","unstructured":"Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with hepatitis C virus: a systematic review and narrative synthesis of qualitative literature. Can J Gastroenterol Hepatol. 2017;2017:3268650.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"suppl_2","key":"475_CR34","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1093\/cid\/cit263","volume":"57","author":"C Treloar","year":"2013","unstructured":"Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013;57(suppl_2):S51\u2013S5.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"475_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1357034X09347221","volume":"15","author":"M Harris","year":"2009","unstructured":"Harris M. Injecting, infection, illness: abjection and hepatitis C stigma. Body Soc. 2009;15(4):33\u201351.","journal-title":"Body Soc"},{"issue":"2","key":"475_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/09581590600828683","volume":"16","author":"S Fraser","year":"2006","unstructured":"Fraser S, Treloar C. 'Spoiled identity' in hepatitis C infection: the binary logic of despair. Crit Public Health. 2006;16(2):99\u2013110.","journal-title":"Crit Public Health"},{"issue":"10","key":"475_CR37","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/j.1360-0443.2008.02306.x","volume":"103","author":"T Rhodes","year":"2008","unstructured":"Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008;103(10):1593\u2013603.","journal-title":"Addiction."},{"issue":"9","key":"475_CR38","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1177\/1049732309341656","volume":"19","author":"C Treloar","year":"2009","unstructured":"Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res. 2009;19(9):1321\u201334.","journal-title":"Qual Health Res"},{"issue":"13\u201314","key":"475_CR39","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/jocn.14083","volume":"27","author":"D Whiteley","year":"2018","unstructured":"Whiteley D, Whittaker A, Elliott L, Cunningham-Burley S. Hepatitis C in a new therapeutic era: Recontextualising the lived experience. J Clin Nurs. 2018;27(13\u201314):2729\u201339.","journal-title":"J Clin Nurs"},{"issue":"7","key":"475_CR40","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1467-9566.2009.01172.x","volume":"31","author":"M Harris","year":"2009","unstructured":"Harris M. Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis. Sociol Health Illness. 2009;31(7):1028\u201342.","journal-title":"Sociol Health Illness"},{"issue":"1","key":"475_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12939-021-01420-7","volume":"20","author":"T Goodyear","year":"2021","unstructured":"Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. \u201cI want to get better, but\u2026\u201d: identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. Int J Equity Health. 2021;20(1):1\u201314.","journal-title":"Int J Equity Health"},{"key":"475_CR42","volume-title":"Hepatitis C among drug users in Europe: epidemiology, Treatment and prevention: Publication Office of the European Union","author":"I Giraudon","year":"2016","unstructured":"Giraudon I, Wiessing L, Hedrich D, Kalamara E, Griffiths P, Simon R. Hepatitis C among drug users in Europe: epidemiology, Treatment and prevention: Publication Office of the European Union; 2016."},{"key":"475_CR43","doi-asserted-by":"crossref","unstructured":"Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high\u2010income countries. Liver International. 2020 Mar;40(3):522\u20139.","DOI":"10.1111\/liv.14324"},{"key":"475_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102766","volume":"81","author":"T Goodyear","year":"2020","unstructured":"Goodyear T, Ti L, Carrieri P, Small W, Knight R. \u201cEverybody living with a chronic disease is entitled to be cured\u201d: challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy. 2020;81:102766.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"475_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2012.11.004","volume":"58","author":"SA McDonald","year":"2013","unstructured":"McDonald SA, Hutchinson SJ, Palmateer NE, Allen E, Cameron SO, Goldberg DJ, et al. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. J Hepatol. 2013;58(3):460\u20136.","journal-title":"J Hepatol"},{"key":"475_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.drugpo.2016.10.013","volume":"38","author":"D Whiteley","year":"2016","unstructured":"Whiteley D, Whittaker A, Elliott L, Cunningham-Burley S. The lived experience of interferon-free treatments for hepatitis C: a thematic analysis. Int J Drug Policy. 2016;38:21\u20138.","journal-title":"Int J Drug Policy"},{"key":"475_CR47","doi-asserted-by":"publisher","unstructured":"Rance J, Rhodes T, Lancaster K. Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: situated potentials and limits. Health. 2021. https:\/\/doi.org\/10.1177\/1363459320988887.","DOI":"10.1177\/1363459320988887"},{"key":"475_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.drugpo.2017.03.015","volume":"47","author":"M Harris","year":"2017","unstructured":"Harris M. Managing expense and expectation in a treatment revolution: problematizing prioritisation through an exploration of hepatitis C treatment \u2018benefit\u2019. Int J Drug Policy. 2017;47:161\u20138.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"475_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41124-018-0036-5","volume":"3","author":"JA Richmond","year":"2018","unstructured":"Richmond JA, Ellard J, Wallace J, Thorpe R, Higgs P, Hellard M, et al. Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatol Med Policy. 2018;3(1):1\u20139.","journal-title":"Hepatol Med Policy"},{"key":"475_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.016","volume":"72","author":"J Grebely","year":"2019","unstructured":"Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C. International network on hepatitis in substance users. Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy. 2019;72:1\u201310.","journal-title":"Int J Drug Policy"},{"key":"475_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.drugpo.2019.03.015","volume":"72","author":"BE Williams","year":"2019","unstructured":"Williams BE, Nelons D, Seaman A, Witkowska M, Ronan W, Wheelock H, et al. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Int J Drug Policy. 2019;72:138\u201345.","journal-title":"Int J Drug Policy"},{"key":"475_CR52","doi-asserted-by":"crossref","unstructured":"Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. \u201cStigma is where the harm comes from\u201d: Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. Int J Drug Policy. 2021;96:103238.","DOI":"10.1016\/j.drugpo.2021.103238"},{"key":"475_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.drugpo.2019.05.011","volume":"72","author":"M Caven","year":"2019","unstructured":"Caven M, Malaguti A, Robinson E, Fletcher E, Dillon JF. Impact of hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: a systematic review. Int J Drug Policy. 2019;72:169\u201376.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"475_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1071\/PY20013","volume":"26","author":"D Pourmarzi","year":"2020","unstructured":"Pourmarzi D, Smirnov A, Hall L, FitzGerald G, Rahman T. \u2018I\u2019m over the moon!\u2019: Patient-perceived outcomes of hepatitis C treatment. Aust J Primary Health. 2020;26(4):319\u201324.","journal-title":"Aust J Primary Health"},{"issue":"2","key":"475_CR55","first-page":"121","volume":"2","author":"S Conrad","year":"2006","unstructured":"Conrad S, Garrett L, Cooksley W, Dunne M, MacDonald G. Living with chronic hepatitis C meansyou just haven't got a normal life any more'. Chronic Illness. 2006;2(2):121\u201331.","journal-title":"Chronic Illness"},{"key":"475_CR56","doi-asserted-by":"crossref","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduction Journal. 2018;15(1):1\u20138.","DOI":"10.1186\/s12954-018-0248-4"},{"issue":"1","key":"475_CR57","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12879-020-05426-4","volume":"20","author":"M Torrens","year":"2020","unstructured":"Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infect Dis. 2020;20(1):702.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"475_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/135910530100600606","volume":"6","author":"EA Dunne","year":"2001","unstructured":"Dunne EA, Quayle E. The impact of iatrogenically acquired hepatitis C infection on the well-being and relationships of a group of Irish women. J Health Psychol. 2001;6(6):679\u201392.","journal-title":"J Health Psychol"},{"issue":"12","key":"475_CR59","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s11606-008-0790-y","volume":"23","author":"EJ Groessl","year":"2008","unstructured":"Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med. 2008;23(12):1959\u201365.","journal-title":"J Gen Intern Med"},{"key":"475_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fpsyg.2015.01795","volume":"6","author":"GA Dingle","year":"2015","unstructured":"Dingle GA, Cruwys T, Frings D. Social identities as pathways into and out of addiction. Front Psychol. 2015;6:12.","journal-title":"Front Psychol"},{"key":"475_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addbeh.2014.10.023","volume":"44","author":"D Frings","year":"2015","unstructured":"Frings D, Albery IP. The social identity model of cessation maintenance: formulation and initial evidence. Addict Behav. 2015;44:35\u201342.","journal-title":"Addict Behav"},{"key":"475_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.psychres.2016.11.039","volume":"247","author":"NF Praharso","year":"2017","unstructured":"Praharso NF, Tear MJ, Cruwys T. Stressful life transitions and wellbeing: a comparison of the stress buffering hypothesis and the social identity model of identity change. Psychiatry Res. 2017;247:265\u201375.","journal-title":"Psychiatry Res"},{"issue":"1","key":"475_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13011-015-0041-2","volume":"10","author":"E Mawson","year":"2015","unstructured":"Mawson E, Best D, Beckwith M, Dingle G, Lubman D. Social identity, social networks and recovery capital in emerging adulthood: a pilot study. Subst Abuse Treat Prev Policy. 2015;10(1):45.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"475_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/16066359.2015.1075980","volume":"24","author":"D Best","year":"2016","unstructured":"Best D, Beckwith M, Haslam C, Alexander Haslam S, Jetten J, Mawson E, et al. Overcoming alcohol and other drug addiction as a process of social identity transition: the social identity model of recovery (SIMOR). Addict Res Theory. 2016;24(2):111\u201323.","journal-title":"Addict Res Theory"},{"issue":"10","key":"475_CR65","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/S0277-9536(99)00409-8","volume":"50","author":"J McIntosh","year":"2000","unstructured":"McIntosh J, McKeganey N. Addicts' narratives of recovery from drug use: constructing a non-addict identity. Soc Sci Med. 2000;50(10):1501\u201310.","journal-title":"Soc Sci Med"},{"key":"475_CR66","doi-asserted-by":"crossref","unstructured":"Jetten J, Haslam C, Alexander SH. The social cure: identity, health and well-being: Psychology press; 2012.","DOI":"10.4324\/9780203813195"},{"key":"475_CR67","volume-title":"Social learning conceptualization for substance abuse: Implications for therapeutic interventions","author":"T Giovazolias","year":"2014","unstructured":"Giovazolias T, Themeli O. Social learning conceptualization for substance abuse: Implications for therapeutic interventions; 2014."},{"key":"475_CR68","volume-title":"European monitoring Centre of Drugs and Drug Addiction (EMCDDA), Insights. Models of Addiction. EMCDDA","author":"R West","year":"2013","unstructured":"West R. European monitoring Centre of Drugs and Drug Addiction (EMCDDA), Insights. Models of Addiction. EMCDDA. Luxembourg: Publications Office of the European Union, Lisbon, Portugal; 2013."},{"key":"475_CR69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev.soc.34.040507.134601","volume":"34","author":"KP Smith","year":"2008","unstructured":"Smith KP, Christakis NA. Social networks and health. Annu Rev Sociol. 2008;34:405\u201329.","journal-title":"Annu Rev Sociol"},{"key":"475_CR70","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3389\/fpsyg.2015.00739","volume":"6","author":"M Johnstone","year":"2015","unstructured":"Johnstone M, Jetten J, Dingle GA, Parsell C, Walter ZC. Discrimination and well-being amongst the homeless: the role of multiple group membership. Front Psychol. 2015;6:739.","journal-title":"Front Psychol"},{"issue":"1","key":"475_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jasp.12420","volume":"47","author":"R Bathish","year":"2017","unstructured":"Bathish R, Best D, Savic M, Beckwith M, Mackenzie J, Lubman DI. \u201cIs it me or should my friends take the credit?\u201d the role of social networks and social identity in recovery from addiction. J Appl Soc Psychol. 2017;47(1):35\u201346.","journal-title":"J Appl Soc Psychol"},{"issue":"2","key":"475_CR72","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bjso.12081","volume":"54","author":"GA Dingle","year":"2015","unstructured":"Dingle GA, Stark C, Cruwys T, Best D. Breaking good: breaking ties with social groups may be good for recovery from substance misuse. Br J Soc Psychol. 2015;54(2):236\u201354.","journal-title":"Br J Soc Psychol"},{"key":"475_CR73","first-page":"117822181987657","volume":"13","author":"B Collinson","year":"2019","unstructured":"Collinson B, Best D. Promoting recovery from substance misuse through engagement with community assets: asset based community engagement. Subst Abus. 2019;13:1178221819876575.","journal-title":"Subst Abus"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-022-00475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-022-00475-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-022-00475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T23:07:18Z","timestamp":1668380838000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-022-00475-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1186\/s13011-022-00475-1","relation":{},"ISSN":["1747-597X"],"issn-type":[{"type":"electronic","value":"1747-597X"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"17 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approvals were not required for this scoping review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SRD declaration of interest: none. AR declares receipt of research grants from Abbvie, BMS, Pfizer and Gilead. Lecture fees and honorariums from Abbvie and Gilead. JFD declares receipt of research grants, Lecture fees and honorariums from Abbvie, BMS, Gilead, MSD and Roche.The sponsors had no role in the design, execution, interpretation, or writing of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}